European Commission rejects Ipsen’s ultra-rare disease drug after two negative opinions from EMA

The Eu­ro­pean Com­mis­sion has re­ject­ed Ipsen’s po­ten­tial new drug palo­varotene for those with the ul­tra-rare ge­net­ic con­nec­tive tis­sue dis­or­der known as fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va, or FOP.

The de­ci­sion fol­lows two neg­a­tive opin­ions from the Eu­ro­pean Med­i­cines Agency in Jan­u­ary and May. And where­as the US FDA re­cent­ly said it might be open to a post-hoc analy­sis of a failed late-stage tri­al for palo­varotene, the EMA said in May:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN